TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $5.91 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.